Trial Profile
A Retrospective Study Assessing Factors Associated with Functional Outcome or Disease Severity of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (PML)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 24 Aug 2017 New trial record